The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

SITC 2021 | Targeting Siglec-15 with NC318 in Siglec-15-positive advanced solid tumors

Name: Targeting Siglec-15 with NC318 in Siglec-15-positive advanced solid tumors
Uploaded: 2021-11-12T00:00:00Z
Duration: 1 min 29 s
Description: Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, outlines the clinical benefit of targeting Siglec-15 with the monoclonal antibody NC318 in patients with Siglec-15-positive advanced solid tumors. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Omid Hamid • 12 Nov 2021

SITC 2021

Breast Cancer General Head and Neck Cancer Lung Cancer Antibodies NC318

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, outlines the clinical benefit of targeting Siglec-15 with the monoclonal antibody NC318 in patients with Siglec-15-positive advanced solid tumors. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.